Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Virtually unknown just months ago, New York congressional candidate Alexandria Ocasio-Cortez arrived in Los Angeles as a rising political star, about a month after her improbable upset of 10-term U.S. Rep. Joe Crowley in a New York City Democratic primary. On Thursday, she intentionally avoided politicians and Hollywood celebrities, instead choosing to share the stage at the low-dollar fundraiser with activists pushing for broader rent-control laws in California and a public-backed banking system in the city. In her speech, she warned of a broken economy in which luxury apartments stand vacant while homeless crowd the streets, and talked of a Democratic Party in which the working class and marginalized are ascendant. Bursts of applause followed her calls for universal health care and a cost-free education through college. She swiped repeatedly, if indirectly, at President Donald Trump. “It is not us who are crazy, not with that man in the White House,” the former Bernie Sanders organizer said to cheers. Ocasio-Cortez was lauded by those who paid $27, or $10 for students, to see the candidate seen as the new face of the emerging democratic socialist movement. “She really inspires me, because she’s so young and she’s getting so far,” said Melainey Jane Foerster, 16, a high-school student from suburban Santa Clarita. Salesman Jon Pelzer, 65, said he’s “impressed by and energized by what she was able to do in New York.” “We share all the same values,” added Pelzer, a Democrat who ran on a similar platform in California’s 30th Congressional District but didn’t advance to November. The surprise victory by the political novice in a district that includes parts of the Bronx and Queens came after a low-budget campaign that she built around liberal and social causes, not the traditional Democratic Party machine. Crowley had been expected to win easily. Her platform includes expanding the Medicare program to people of all ages and abolishing Immigrations and Customs Enforcement. Her trip to California comes at a time when state and national Democrats have been contending with friction between their establishment and liberal wings. California Sen. Dianne Feinstein is being challenged in November by a fellow Democrat, state Sen. Kevin de Leon, who has positioned himself as a liberal alternative to the long-serving centrist. She warned of the influence of “coastal elites” in politics, and she recalled that her candidacy was largely dismissed. Ocasio-Cortez said she didn’t receive an endorsement from any incumbent “but we won anyway.” She urged the crowd to “engage in the fights that you know that are right.” Claim: Rising liberal Democrat star on West Coast fundraising swing.

Output: She visited Los Angeles’ notorious Skid Row neighborhood, where the homeless crowd the streets. She met with liberal activists eager to see universal health care and expanded rent-control laws. And she was cheered by hundreds of supporters at a downtown fundraiser, where she warned of those who scheme to turn liberal-minded Americans against each other.


Input: Consider Input: Paragraph: In January 2020, readers asked us about the accuracy of a story that claimed the U.S. Food and Drug Administration (FDA) had approved a new cocaine nasal spray for use as a local anesthetic. On Jan. 13, the cannabis and drug industry website Merry Jane published an article with the headline “A Cocaine Nasal Spray Just Received FDA Approval.” That article reported that: Medicinal cocaine has always been a thing, but now there’s an FDA-approved nasal spray aptly made with totally legal, pharmaceutical-grade white. On Monday, the pharmaceutical outfit Lannett Company announced that its new cocaine hydrochloride nasal spray product, dubbed Numbrino, cleared two Phase III, randomized, double-blind clinical trials. “The FDA’s approval of our cocaine HCl product, the first NDA approval to include full clinical trials in the company’s history, marks a major milestone in Lannett’s 70+ years of operations,” said Tim Crew, Lannett Company’s CEO, in a press release. “We believe the product has the potential to be an excellent option for the labeled indication. We expect to launch the product shortly …” The pharmaceutical company’s press release, also published on Jan. 13, read as follows: “Lannett Company, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company’s branded local anesthetic product … NUMBRINO® (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.” Claim: In January 2020, the Food and Drug Administration approved a nasal spray containing cocaine. 

Output: The press release, and Merry Jane’s article, were accurate. In a Jan. 10 letter addressed to Cody Laboratories, a subsidiary of the Philadelphia-headquartered Lannett, the FDA’s Center for Drug Evaluation and Research wrote:


Input: Consider Input: Paragraph: "The story mentioned alli would cost between $2-$3 per day. The claim for this over-the-counter version of this medication was that it will have similar effect on weight loss as the dose available by prescription. However, data from the original studies designed to examine effectiveness of this medication show that the weight loss observed was dose dependent. These data suggest that the anticipated weight loss should be about half of that seen with the prescription version. Although the story alluded several times to a 10-20 pound weight loss, it failed to provide a time frame for this weight loss or any indication that weight regain was common after cessation of the drug. Although the story lists some of the gastro-intestinal unpleasantries that occur with the use of this medication, a quote from a paper put out by the FDA  (http://www.fda.gov/bbs/topics/ANSWERS/ANS00951.html ) on the prescription strength form of the drug really says it better:  ""The most common side effects of orlistat are oily spotting, gas with discharge, fecal urgency, fatty/oily stools and frequent bowel movements."" The story also included concerns regarding the potential for deficiency of fat-soluble vitamins occuring with the use of this medication. The story did not include a warning for organ transplant recipients for whom this medication could cause serious problems. But it did mention concerns regarding the potential for deficiency of fat-soluble vitamins occuring with the use of this medication. The story included a quote from the director of health research at Public Citizen regarding concerns about ""precancerous lesions of the colon"" derived from a single study in rats. There is currently no published data supporting similar concerns about use of this drug in humans. The story included information from one weight loss specialist that the use of this product results in an average weight loss of 10-16 pounds. It did not mention that this was with the use of the prescription strength product, in the setting of a weight loss practice which likely included supportive interactions with health care professionals as well as reduction in calories consumed and increased exercise. Near the end of the story, there was information (""..eating a low-fat diet containing no more than 15 grams of fat per meal would reduce the risk of the side effect."") attributed to the FDA. This sentence is actually a direct quote from the www.myalli.com website. No overt disease-mongering about obesity; about two thirds of the way through it mentions that ~130 million Americans are overweight, and that about half of these would be considered obese. There were many clinicians, FDA personnel, and company spokesperson quoted for this story. The views from clinicians included those who said that this product will not result in weight loss on its own. It might have been helpful to include a link to the information released by the FDA on this product. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01557.html This story did not discuss other treatment options for the loss of comparable amounts of weight This story is about a new product, alli, which has been approved by the FDA for sale without a prescription. The story reported that it will be available this summer. The story was clear that alli is an over-the-counter strength of a medication that has previously been available by prescription only. Several sources were used, so it appears unlikely the story relied solely or largely on a news release." Claim: Nonprescription diet drug gets OK


Output: "This is a story crafted around the news that the FDA has approved  the sale of a lower dose, over-the-counter (OTC) version of the diet medication orlistat. The story insinuates that the OTC version would have a similar effect on weight loss as does the prescription strength. Although both are likely to be associated with weight loss, the data suggest that the weight loss is dose dependent, so the anticipated weight loss should be about half of that seen with the prescription version. Although the story alluded several times to a 10-20 pound weight loss, it failed to provide a time frame for this weight loss or any indication that weight regain was common after cessation of the drug. Quotes from several clinicians, FDA officials, and the makers of the medication were included in this piece. Some sources expressed appropriate caveats about safety and about efficacy of the new OTC product. Although the story lists some of the gastro-intestinal unpleasantries that occur with the use of this medication, a quote from a paper put out by the FDA  (http://www.fda.gov/bbs/topics/ANSWERS/ANS00951.html ) on the prescription strength form of the drug really says it better:  ""The most common side effects of orlistat are oily spotting, gas with discharge, fecal urgency, fatty/oily stools and frequent bowel movements."""